| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
OSR Holdings, Inc.$0.39
+0.01 (+1.51%)
D 22Pipeline Score MedTech · Clinical
Market Cap
17.62 M
EPS
-0.36
P/E Ratio
-
Value Trade
792.20 K
SEC Financials
Q1 2026Dilution Risk
Revenue
484.06 K
R&D Expenses
113.15 K
Operating CF
-1.00 M
Total Assets
172.19 M
Total Liabilities
44.80 M
Equity
127.39 M
D/E Ratio
12,345
-16.33 %
Week
-14.92 %
1 Month
13.17 %
3 Month
-17.12 %
6 Month
-95.03 %
5 Year
-95.03 %
All Time
Cash Data
Cash Position
1.57 M
Monthly Burn
334.00 K
Runway
3.5 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
816.23 K
52 Week Range
0.38 - 1.79
% held by Insiders
44.77 %
% held by Institutions
0.83 %
Enterprise Value
44.54 M
Total Shares
26.61 M
Short %
6.1 %
Float Shares
12.03 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D22
Pipeline Score $0M
Pipeline ValueValuation Signal
2
Drugs Scored0.0x
rNPV / MCap Top 21%
Micro Cap (rank 716 of 905)
Percentile RankOSR Holdings, Inc. faces pipeline headwinds (22/100), with $79M risk-adjusted pipeline value, led by VXM01 in Stage IV Pancreatic Cancer (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VXM01 Monoclonal antibody | Stage IV Pancreatic Cancer | Phase 1 | NCT01486329 | 17% | $79M | COMPLETED | 72 | - | - | Dec 1, 2014 | - | Jun 8, 2015 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Glucheck | Diabetes Management | Phase 1 | 2025-11-06 | |||
Glucheck | Diabetes Management | Phase 1 | 2025-11-06 | |||
Glucheck | Diabetes Management | Phase 1 | 2025-11-06 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OSRH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
OSRH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
OSRH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
OSRH
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
OSRH Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
OSRH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
OSRHWoori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials
OSR Holdings' subsidiary, Woori IO, has signed a non-disclosure agreement with Sinopharm to explore regulatory and commercial pathways for its noninvasive glucose monitoring technology in China. This partnership aims to leverage Sinopharm's extensive distribution network in a rapidly growing diabetes market. The collaboration may lead to global multicenter trials and further strategic partnerships.
Read more →OSRHOSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries
OSR Holdings, Inc. has completed its acquisition of Woori IO, enhancing its medical device and digital health platform. The historical shareholders of Woori IO have reaffirmed a three-year equity alignment with OSRH, aimed at preventing dilution. Additionally, OSRH is reviewing a potential combination of its medical device subsidiaries to create a new integrated company, leveraging the strengths of both entities.
Read more →OSRHVaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform
Vaximm AG has appointed Dr. Sébastien Wieckowski as Chief Scientific Officer to enhance its oral immunotherapy platform. His extensive experience in immunology and data science is expected to drive innovation and optimize the company's lead candidate, VXM01, as it progresses into later-stage clinical trials. This strategic move aims to expand Vaximm's capabilities in oncology and other therapeutic areas.
Read more →OSRHOSR Holdings Provides Transparency Update on Equity Financing Instruments
OSR Holdings, Inc. has provided a transparency update on its Equity Line of Credit (ELOC) agreement, emphasizing that future issuances will not be purely dilutive. CEO Peter Hwang highlighted that proceeds will be invested in the company's drug R&D pipeline and medical device initiatives. The company aims to protect shareholder value and believes its current share price does not reflect its intrinsic value.
Read more →OSRHOSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure
OSR Holdings, Inc. has provided a strategic update on its Term Sheet with Woori IO Co., Ltd., which will make WORIO a wholly owned subsidiary. WORIO shareholders will receive OSRK shares with a conditional right to exchange for OSRH stock if the share price reaches $10.00 within three years. This transaction aims to capitalize on the growing demand for noninvasive glucose monitoring technology, positioning OSRH favorably in a market projected to exceed $40 billion by 2030.
Read more →OSRHOSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring TechnologyUSA - EnglishKorea - 한국어
OSR Holdings has signed a term sheet to acquire Woori IO, a South Korean company specializing in noninvasive glucose monitoring technology. This acquisition aims to enhance OSR's portfolio in diabetes management solutions. Woori IO's technology promises pain-free glucose monitoring, potentially integrating into wearable devices. The deal includes a share exchange contingent on OSRH's stock performance.
Read more →OSRHOSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company
OSR Holdings has appointed Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG. Dr. Niethammer, an expert in oncology with extensive experience in cancer immunotherapy, will lead Vaximm's clinical strategy. His leadership is anticipated to enhance the development of VXM01, an oral T-cell activator, and expand the company's oncology pipeline.
Read more →OSRHOSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AGIndia - EnglishUSA - EnglishAPAC - English
OSR Holdings, Inc. has announced a strategic roadmap for a $50 million security token offering (STO) under Regulation D, set to launch in the second half of 2025. The OSRT token will represent equity exposure and will accept various cryptocurrencies, including Bitcoin, Tether, and the Taekwondo Access Credit (TAC). The company aims to enhance investor engagement while maintaining regulatory compliance and operational integrity.
Read more →OSRHOSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG
OSR Holdings has announced a strategic roadmap for a $50 million security token offering (STO) under Regulation D, set to launch in late 2025. The OSRT token will represent equity exposure and can be purchased using Bitcoin, Tether, or the Taekwondo Access Credit (TAC) token. The initiative aims to enhance investor engagement while ensuring regulatory compliance.
Read more →OSRHOSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token
OSR Holdings has signed a Memorandum of Understanding with BCM Europe AG and Taekwondo Cooperative to develop the OSRH Token, a blockchain-based security token. This initiative aims to enhance access to crypto liquidity and explore decentralized financing models. The token will accept various crypto assets, including Bitcoin and Tether, and is expected to integrate with the existing Taekwondo Access Credit infrastructure.
Read more →OSRHDarnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics
Darnatein, a subsidiary of OSR Holdings, will present at the 14th International BMP Conference from May 2-6, 2025, in Philadelphia. CEO Dr. Senyon Choe will discuss their proprietary platform technology and novel biologic candidates DRT-101 and DRT-102, aimed at joint cartilage and spinal bone regeneration. This participation emphasizes Darnatein's leadership in synthetic regenerative biologics.
Read more →Competitive Position
How OSRH ranks across every disease it competes inCompetitive Position is a premium feature
See how OSRH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial